Meletios A. Dimopoulos, MD, on Multiple Myeloma: Daratumumab, Pomalidomide, and Dexamethasone

December 10, 2020 By The ASCO Post Staff

Meletios A. Dimopoulos, MD, of the University of Athens, discusses data from the phase III APOLLO study, which evaluated the use of subcutaneous daratumumab plus pomalidomide and dexamethasone, vs pomalidomide and dexamethasone alone, in patients with relapsed or refractory multiple myeloma (Abstract 412).

Related Content